Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

First Oral Blood Thinner Is Approved for Children

First Oral Blood Thinner Is Approved for Children News & Analysis News From the Food and Drug Administration New Option for Patients With Allergy cayetanensis bacterium, the FDA and the intend to work with the CDC to examine to Chemotherapy Component US Centers for Disease Control and Pre- trends in US cyclosporiasis outbreaks. The FDA has approved an alternative for vention (CDC) have developed an action patients with acute lymphoblastic leuke- plan focused on detection, prevention, First Oral Blood Thinner Is Approved mia or lymphoblastic lymphoma who and education. for Children are allergic to Escherichia coli–derived Over the past 3 years, CDC data indi- The FDA approved dabigatran etexilate as asparaginase products in their chemo- cate that more than 6000 cyclosporiasis the first oral blood thinner for children aged 3 months to 11 years who have venous therapy regimen. cases have been traced to US produce. Marketed as Rylaze, asparaginase Previously, most US cases were linked with thromboembolism and received injectable blood thinners for at least 5 days. Previ- Erwinia chrysanthemi (recombinant)– travel to endemic areas or eating contami- rywn, is indicated for adults and children nated imported produce. However, the ously, the only anticoagulant approved for children was an injectable formulation. aged 1 month or older. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA American Medical Association

First Oral Blood Thinner Is Approved for Children

JAMA , Volume 326 (7) – Aug 17, 2021

First Oral Blood Thinner Is Approved for Children

Abstract

News & Analysis News From the Food and Drug Administration New Option for Patients With Allergy cayetanensis bacterium, the FDA and the intend to work with the CDC to examine to Chemotherapy Component US Centers for Disease Control and Pre- trends in US cyclosporiasis outbreaks. The FDA has approved an alternative for vention (CDC) have developed an action patients with acute lymphoblastic leuke- plan focused on detection, prevention, First Oral Blood Thinner Is Approved mia or...
Loading next page...
 
/lp/american-medical-association/first-oral-blood-thinner-is-approved-for-children-8dzfFbRKRf
Publisher
American Medical Association
Copyright
Copyright 2021 American Medical Association. All Rights Reserved.
ISSN
0098-7484
eISSN
1538-3598
DOI
10.1001/jama.2021.13259
Publisher site
See Article on Publisher Site

Abstract

News & Analysis News From the Food and Drug Administration New Option for Patients With Allergy cayetanensis bacterium, the FDA and the intend to work with the CDC to examine to Chemotherapy Component US Centers for Disease Control and Pre- trends in US cyclosporiasis outbreaks. The FDA has approved an alternative for vention (CDC) have developed an action patients with acute lymphoblastic leuke- plan focused on detection, prevention, First Oral Blood Thinner Is Approved mia or lymphoblastic lymphoma who and education. for Children are allergic to Escherichia coli–derived Over the past 3 years, CDC data indi- The FDA approved dabigatran etexilate as asparaginase products in their chemo- cate that more than 6000 cyclosporiasis the first oral blood thinner for children aged 3 months to 11 years who have venous therapy regimen. cases have been traced to US produce. Marketed as Rylaze, asparaginase Previously, most US cases were linked with thromboembolism and received injectable blood thinners for at least 5 days. Previ- Erwinia chrysanthemi (recombinant)– travel to endemic areas or eating contami- rywn, is indicated for adults and children nated imported produce. However, the ously, the only anticoagulant approved for children was an injectable formulation. aged 1 month or older.

Journal

JAMAAmerican Medical Association

Published: Aug 17, 2021

There are no references for this article.